Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(50.0%)
Phase 2
4(50.0%)
8Total
Phase 1(4)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06741345Phase 1Completed

Phase 1 BIO 300 Oral Suspension

Role: lead

NCT04482595Phase 2Active Not Recruiting

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

Role: lead

NCT04650555Phase 1Completed

BIO 300 Oral Powder Safety and Pharmacokinetics

Role: lead

NCT02567799Phase 1Completed

BIO 300 Non-Small Cell Lung Cancer Study

Role: lead

NCT00470418Phase 2Completed

Development of NIC5-15 in the Treatment of Alzheimer's Disease

Role: collaborator

NCT01928420Phase 2Completed

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease

Role: lead

NCT01861847Phase 2Completed

7-Keto DHEA for the Treatment of PTSD

Role: lead

NCT00504335Phase 1Completed

Safety and Pharmacokinetic Study of BIO 300 Capsules

Role: lead

All 8 trials loaded